Potential pharmacological approach in the regulation of ACE-2 and DPP-IV in diabetic COVID-19 patient

The global pandemic caused by COVID-19 has caused more than 1 million deaths worldwide. Some vaccines in clinical trials have reached stage 3. In the meantime, the understanding of the biological and pathophysiological mechanisms of Sars-CoV2 infection is still unclear, such as the role that ACE-2 and DPP-IV may play in patients with diabetes related to COVID-19. The individual with diabetes is a known COVID-19 risk patient. Probably the pharmacological regulation of the RAS system and of ACE-2 on the one hand, and of the incretin system and DPP-IV on the other, could represent a therapeutic route of fundamental importance to reduce the risk of Sars-CoV-2 infection or of serious complications caused by infection.